



2nd Annual CMOD Canadian Biomarkers and Surrogate Endpoints Meeting "Biomarkers and Personalized Medicine"

May 17, 2010
8:30 am – 5:00 pm

Banting Theatre, Health Canada Campus
Tunney's Pasture, Ottawa, Ontario

Program co-
chairs:



Dr. Jean-Claude Tardif,
Research Director,
Montreal Heart
Institute

Dr. Agnes Klein,
Director,
Center for
Evaluation of
Radiopharm
and
Biotherapeutics
Health Canada



Dr. Peter Libby,
Mallinckrodt
Professor of
Medicine,
Harvard
Medical
School



Sponsored by:

Health Canada

**International Partnership for Critical Markers of
Disease (CMOD)**

**Center of Excellence in Personalized Medicine
(CEPMed)**

**Canadian Atherosclerosis Imaging Network
(CAIN)**

Canadian Institutes of Health Research (CIHR)



2nd Annual CMOD Canadian Biomarkers and Surrogate Endpoints Meeting "Biomarkers and Personalized Medicine"

REGISTRATION FORM – Deadline May 10, 2010

REGISTRATION FEE:

INDUSTRY/COMMERCIAL _____ \$495.00
 FULL TIME HEALTH CANADA EMPLOYEE _____ NO FEE
 ACADEMIC AFFILIATED _____ NO FEE

Participants are responsible for their own meals, hotel and travel arrangements

First Name:		Phone:	
Last Name:		Fax:	
Organization:			
E-Mail:			
Mailing Address:	Street 1:		
	Street 2:		
	City:	State:	Postal:
Billing Address: <small>(if paying by credit card, billing address must match address on credit card)</small>	Street 1:		
	Street 2:		
	City:	State:	Postal:
Payment Type:	Check:	Credit:	
	If Paying By Credit Card: <small>Please complete the following</small>		
	Credit Card Type:	Exp. Date:	
	Acct #:	CSC:back #	
	Signature:	Date:	

Fax registration accepted at any time for credit card payment only. Otherwise, mail the registration and fee payable to International Partnership for Critical Markers of Disease, PO Box 361, 24 Frank Lloyd Wright Drive, Ann Arbor, MI, 48106.

Phone: 810-923-9108

Fax: 810-229-6424

Website: www.cmod.org

Preliminary Agenda – May 17, 2010

8:30 - 8:40 AM	Opening Remarks and Introduction
8:40 – 9:00 AM	The Personalized Medicine Landscape Clarissa Desjardins, CEPMED
9:00 – 9:20 AM	Rewards and Risks of Using Biomarkers in Drug Development Agnes Klein, Health Canada
9:20 – 9:40 AM	CIHR Initiatives - Advancing Research and Practice Peter Liu, CIHR/ U Toronto
9:40 – 10:00 AM	Imaging as a fine phenotyping modality to validate biomarkers J-C Tardif, Montreal Heart
10:00 – 10:20 PM	BREAK
10:20 – 10:40 AM	GWAS and sequencing studies John Rioux, Montreal Heart Institute
10:40 – 11:00 AM	Pharmacogenomics Michael Phillips, Montreal Heart Institute
11:00 – 12:00 PM	PANEL DISCUSSION
12:00 – 1:00 PM	LUNCH BREAK
1:00 – 1:20 PM	Novel Approaches and Clinical Utility Peter Libby, Harvard Medical School
1:20 - 1:40 PM	Clopidogrel and genetic variance Jessica Mega, Brigham and Women's Hospital
1:40 – 2:00 AM	Hepatic Safety Brian Foster, Health Canada
2:00 – 2:20 AM	Molecular Imaging and Personalized Medicine Donald Black, CMOD
2:20 – 2:40 PM	BREAK
2:40 – 3:40 PM	Case studies: Pharma / Diagnostic
3:40 – 4:00 PM	Public Policy Narayanan Iyer, Health Canada
4:00 – 5:00 PM	Panel Discussion How can Canada lead in the adoption of personalized medicine strategies?
5:00	Conclusion and Adjourn

2010 CMOD Biomarkers and Surrogate Endpoints Meeting Faculty Chairs

Jean-Claude Tardif, MD, is the Director of the Research Centre and cardiologist at the Montreal Heart Institute and professor of medicine at the University of Montreal. Dr. Tardif graduated from the University of Montreal with his medical degree in 1987 and completed his training in cardiology and research in Montreal and Boston in 1994. Dr. Tardif is the Director of the Cardiovascular Health Network of the Quebec Health Research Fund (FRSQ) and also holds the Canadian Institutes of Health Research (CIHR) and Pfizer chair in atherosclerosis. He is the scientific director of the Montreal Heart Institute Coordinating Centre (MHICC) and chairman of the steering committee of the CIHR-funded Canadian Atherosclerosis Imaging Network (CAIN). Dr. Tardif has authored and co-authored more than 500 articles and abstracts in peer-reviewed publications including The New England Journal of Medicine, The Journal of the American Medical Association, The Lancet, Circulation, and the Journal of the American College of Cardiology. In addition, he has written more than 25 book chapters and has edited several books. He is the principal investigator of several large international clinical trials in the field of atherosclerosis and other cardiovascular diseases. Because of his accomplishments, Dr Tardif was named Fellow of the Canadian Academy of Health Sciences (CAHS).

Agnes V. Klein MD, DPH, is currently the Director, Centre for the Evaluation of Radiopharmaceuticals and Biotherapeutic Products in the Biologics and Genetic Therapies Directorate. After receiving her medical degree from the University of Toronto, Dr. Klein trained in Endocrinology, Medical Biochemistry and Public and Community Health. After joining Health Canada, she has occupied many and varied scientific and management positions Canada and its Amongst relevant accomplishments, Dr. Klein represented Health Canada on NCBHR, as founding member and NCEHR as well as chairing the Committee on Clinical Trials of the Council. In 2000, Dr. Klein moved from the Drugs side of the regulatory Directorates to Biologics and was at the forefront of many of the changes that shaped the current Biologics and Genetic Therapies Directorate. Dr. Klein was an active participant in the CIOMS document on Pharmacogenetics and Pharmacoeconomics. She is also actively participating in the ICH process and, most recently, was the champion of a new Pharmacogenomics Regulatory Guideline issues by Health Canada. Dr. Klein's special interests include the appropriate design of clinical trials and the various and complex ethical issues attendant to the design and conduct of clinical trials and other studies in human subjects. Dr. Klein is a member of Health Canada's Research Ethics. She is an active member of several medical and scientific organizations nationally and internationally.

Peter Libby, MD, is the Chief of Cardiovascular Medicine at the Brigham and Women's Hospital in Boston, MA. He also serves as the Mallinckrodt Professor of Medicine at Harvard Medical School. Dr. Libby directs the D.W. Reynolds Cardiovascular Clinical Research Center at Harvard. His current major research focus is the role of inflammation in vascular diseases such as atherosclerosis. He has received numerous awards and recognitions for his research accomplishments, including the 2006 Distinguished Scientist Award of the American College of Cardiology. His areas of clinical expertise include general and preventive cardiology. An author and lecturer on cardiovascular medicine and atherosclerosis, Dr. Libby has published extensively in medical journals including Circulation, Journal of Clinical Investigation, Proceedings of the National Academy of Sciences, New England Journal of Medicine, and Nature. He is Editor-in-Chief of the current edition of Braunwald's Heart Disease. Dr. Libby has also contributed the chapters on the pathogenesis, treatment, and prevention of atherosclerosis to Harrison's Principles of Internal Medicine. He has held numerous visiting professorships and has been selected to deliver over 50 named or keynote lectures throughout the world. His professional memberships include the Association of American Physicians, the American Society for Clinical Investigation, and honorary membership in the British Atherosclerosis Society. He currently serves as the President of the Association of University Cardiologists. He has served in many roles as a volunteer for the American Heart Association, including chairman of several research committees and member of the executive committees of the Councils on Arteriosclerosis, Circulation, and Basic Science. He has frequently served as a consultant to the National Heart, Lung, and Blood Institute (NHLBI), including a 5-year term on the Board of Scientific Councilors. He was the recipient of a MERIT Award from the NHLBI. Dr. Libby earned his medical degree at the U of California, San Diego, and completed his training in internal medicine and cardiology at the Peter Bent Brigham Hospital (now Brigham and Women's Hospital). He also holds an honorary MA degree from Harvard University and is the 2010 recipient of the Louis and Artur Lucien Award for Research in Circulatory Disease from McGill University.



The International Partnership for Critical Markers of Disease (CMOD) is a non-profit I.R.S. 501c3 tax exempt organization. The mission of CMOD is to accelerate the identification, validation and appropriate application of biomarkers in cardiovascular and related diseases. The broad goal of this non-profit organization is to create efficiencies toward improved patient healthcare. Toward this goal the partnership works to: 1. Provide scientifically rigorous and balanced information on established and novel biomarkers and imaging technologies; 2. Facilitate the cooperative exchange of ideas and information about critical biomarkers among clinical and basic scientists, governmental regulatory agencies, pharmaceutical, biotech and diagnostic companies, healthcare providers, and patient groups; 3. Identify issues in biomarker identification and offer educational programs, which provide access to the most current information on biomarker and related sciences to meet educational needs; and 4. Promote and support collaborative initiatives to advance the identification, validation and application of biomarkers most efficiently. For more information please visit www.cmod.org.

The Canadian Atherosclerosis Imaging Network (CAIN) is a pan-canadian imaging network led by Dr. Jean-Claude Tardif at the Montreal Heart Institute and funded through grants from the Canadian Foundation for Innovation (CFI) and the Canadian Institutes of Health Research (CIHR). This unique research network is focused on the pathobiology of atherosclerotic disease as it pertains to the coronary and carotid circulations. The CAIN research program involves the creation of a unique national network focused on in vivo imaging of vessel wall disease, combined with imaging of occult end-organ disease as well as the acquisition of clinical and pathological end points. CAIN is enabling unprecedented cross-sectional and longitudinal clinical studies of patients with atherosclerotic disease in coronary or carotid vascular beds, and will establish an international resource for studying the natural history, progression, regression and novel therapeutic interventions aimed at atherosclerosis. Collaboration with private organizations are currently being established. For additional information please visit www.canadianimagingnetwork.org.

Cepmed, Centre of Excellence in Personalized Medicine aims to become a world leader in the development of individualized therapeutics by capitalizing on the latest advancements in genomics and biomarker research, and their rapid integration into large scale clinical trials. Given the critical importance of a patient's genetic background in the success or failure of a given therapy, there is an urgent need to introduce approaches and tools that take advantage of these individual variations to streamline the drug development process. The integration of pharmacogenomics and biomarkers into preclinical and clinical development are essential steps to reduce the attrition rate of emerging therapeutics and improve their effectiveness and safety. Cepmed is a member of the Centres of Excellence in Commercialization and Research (CECR), a unique initiative of the Government of Canada to stimulate the development of marketable technologies, products and services by drawing on the outstanding talent and infrastructure available in health and teaching institutions throughout Canada. In particular, Cepmed relies on a tightly knit network of expertise and technological platforms at the Montreal Heart Institute (MHI) and at Genome Quebec, including among others the MHI Research Institute focused on biomarkers, bioinformatics and biobanking of DNA samples (genetic cohort of 30,000 patients), the MHI Coordination Center (MHICC) for clinical trials, the McGill University-Genome Quebec Innovation Centre and the Genome Quebec-MHI Pharmacogenomics Centre, a GLP-compliant, state-of-the-art, multi-platform facility.